SPE board member Alan Chalmers will oversee the office, located at Aeschenvorstadt 71, which will interact with the Swiss Agency for Therapeutic Products on planned future regulatory submissions for clinical research and product marketing.
Ryuji Ueno, president and CEO of Sucampo Pharmaceuticals, said: “Our new Switzerland office continues the expansion of our European operation and builds upon the strength of our current activities. Having a strong presence throughout Europe is an important part of our global product development and marketing strategy.”